283 related articles for article (PubMed ID: 23583302)
21. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.
Cabanillas ME; Williams MD; Gunn GB; Weitzman SP; Burke L; Busaidy NL; Ying AK; Yiin YH; William WN; Lu C; Lai SY
Head Neck; 2017 Jul; 39(7):1291-1295. PubMed ID: 28452157
[TBL] [Abstract][Full Text] [Related]
22. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.
Silver Karcioglu A; Iwata AJ; Pusztaszeri M; Abdelhamid Ahmed AH; Randolph GW
Cancer Cytopathol; 2022 Mar; 130(3):174-180. PubMed ID: 34618407
[No Abstract] [Full Text] [Related]
23. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
24. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review.
Guerra A; Di Crescenzo V; Garzi A; Cinelli M; Carlomagno C; Tonacchera M; Zeppa P; Vitale M
BMC Surg; 2013; 13 Suppl 2(Suppl 2):S44. PubMed ID: 24267151
[TBL] [Abstract][Full Text] [Related]
25. Anaplastic thyroid cancer.
Ranganath R; Shah MA; Shah AR
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
[TBL] [Abstract][Full Text] [Related]
26. Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.
Sugitani I; Onoda N; Ito KI; Suzuki S
J Nippon Med Sch; 2018; 85(1):18-27. PubMed ID: 29540641
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma.
Akaishi J; Sugino K; Kitagawa W; Nagahama M; Kameyama K; Shimizu K; Ito K; Ito K
Thyroid; 2011 Nov; 21(11):1183-9. PubMed ID: 21936674
[TBL] [Abstract][Full Text] [Related]
28. Anaplastic Thyroid Cancer: New Horizons and Challenges.
Maniakas A; Zafereo M; Cabanillas ME
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):391-401. PubMed ID: 35662448
[TBL] [Abstract][Full Text] [Related]
29. Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer.
Li W; Li Y; Li J; Pang H
Technol Cancer Res Treat; 2023; 22():15330338231169870. PubMed ID: 37122242
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological Spectrum of Anaplastic Carcinoma of Thyroid - 5 Year Experience from a Tertiary Cancer Centre.
Manjusha P; Kandathil JP; Nayanar SK; Jones J; Sajith B
Gulf J Oncolog; 2018 Sep; 1(28):17-22. PubMed ID: 30344129
[TBL] [Abstract][Full Text] [Related]
31. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival.
Haigh PI; Ituarte PH; Wu HS; Treseler PA; Posner MD; Quivey JM; Duh QY; Clark OH
Cancer; 2001 Jun; 91(12):2335-42. PubMed ID: 11413523
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of anaplastic thyroid carcinoma in the Kurdistan region of Iraq.
Mustafa DH; Ahmed BS; Haweizy RM; Dewana AM
BMC Surg; 2022 Oct; 22(1):364. PubMed ID: 36271386
[TBL] [Abstract][Full Text] [Related]
33. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
34. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.
Zhou M; Chen Y; Adachi M; Wen X; Erwin B; Mawlawi O; Lai SY; Li C
Biomaterials; 2015 Jul; 57():41-9. PubMed ID: 25913249
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches.
Are C; Shaha AR
Ann Surg Oncol; 2006 Apr; 13(4):453-64. PubMed ID: 16474910
[TBL] [Abstract][Full Text] [Related]
36. Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012.
Brignardello E; Palestini N; Felicetti F; Castiglione A; Piovesan A; Gallo M; Freddi M; Ricardi U; Gasparri G; Ciccone G; Arvat E; Boccuzzi G
Thyroid; 2014 Nov; 24(11):1600-6. PubMed ID: 25110922
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic thyroid cancer: the addition of systemic chemotherapy to radiotherapy led to an observed improvement in survival--a single centre experience and review of the literature.
Lowe NM; Loughran S; Slevin NJ; Yap BK
ScientificWorldJournal; 2014; 2014():674583. PubMed ID: 25184150
[TBL] [Abstract][Full Text] [Related]
38. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Choi HS; Park do J; Jung KC; Sung MW; Kim KH; Hah JH; Park YJ
Thyroid; 2016 Sep; 26(9):1259-68. PubMed ID: 27412715
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy.
Yau T; Lo CY; Epstein RJ; Lam AK; Wan KY; Lang BH
Ann Surg Oncol; 2008 Sep; 15(9):2500-5. PubMed ID: 18581185
[TBL] [Abstract][Full Text] [Related]
40. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
Prasongsook N; Kumar A; Chintakuntlawar AV; Foote RL; Kasperbauer J; Molina J; Garces Y; Ma D; Wittich MAN; Rubin J; Richardson R; Morris J; Hay I; Fatourechi V; McIver B; Ryder M; Thompson G; Grant C; Richards M; Sebo TJ; Rivera M; Suman V; Jenkins SM; Smallridge RC; Bible KC
J Clin Endocrinol Metab; 2017 Dec; 102(12):4506-4514. PubMed ID: 29029287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]